China SXT Pharmaceuticals Inc (SXTC) - Total Liabilities
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has total liabilities worth $6.12 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
China SXT Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how China SXT Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of China SXT Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
China SXT Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Babylon Pump & Power Ltd
AU:BPP
|
Australia | AU$40.25 Million |
|
Evergreen Lithium Ltd
AU:EG1
|
Australia | AU$282.55K |
|
Nisun International Enterprise Development Group Co Ltd
NASDAQ:NISN
|
USA | $87.22 Million |
|
Sonoro Energy Ltd
V:SNV
|
Canada | CA$1.04 Million |
|
Renoworks Software Inc
V:RW
|
Canada | CA$2.31 Million |
|
Evolva Holding SA
SW:EVE
|
Switzerland | CHF812.70K |
|
Spectrumone publ AB
ST:SPEONE
|
Sweden | Skr40.81 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down China SXT Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SXTC company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China SXT Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China SXT Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of China SXT Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $6.22 Million | -32.33% |
| 2024-03-31 | $9.20 Million | -38.12% |
| 2023-03-31 | $14.86 Million | -13.19% |
| 2022-03-31 | $17.12 Million | -7.88% |
| 2021-03-31 | $18.59 Million | +51.10% |
| 2020-03-31 | $12.30 Million | +93.32% |
| 2019-03-31 | $6.36 Million | +45.54% |
| 2018-03-31 | $4.37 Million | +22.17% |
| 2017-03-31 | $3.58 Million | -35.57% |
| 2016-03-31 | $5.55 Million | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu,… Read more